Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DNLI |
---|---|---|
09:32 ET | 10129 | 20.51 |
09:34 ET | 1131 | 20.32 |
09:36 ET | 2284 | 20.41 |
09:38 ET | 100 | 20.34 |
09:39 ET | 400 | 20.33 |
09:41 ET | 2961 | 20.405 |
09:43 ET | 1528 | 20.49 |
09:45 ET | 2315 | 20.57 |
09:48 ET | 1359 | 20.55 |
09:50 ET | 2224 | 20.6 |
09:52 ET | 1184 | 20.62 |
09:54 ET | 2500 | 20.69 |
09:56 ET | 1854 | 20.75 |
09:57 ET | 1425 | 20.735 |
09:59 ET | 3712 | 20.84 |
10:01 ET | 3567 | 20.76 |
10:03 ET | 1086 | 20.725 |
10:06 ET | 500 | 20.52 |
10:08 ET | 4016 | 20.48 |
10:10 ET | 4368 | 20.49 |
10:12 ET | 683 | 20.44 |
10:14 ET | 2420 | 20.43 |
10:15 ET | 920 | 20.45 |
10:17 ET | 2956 | 20.45 |
10:19 ET | 2479 | 20.415 |
10:21 ET | 5233 | 20.41 |
10:24 ET | 2817 | 20.38 |
10:26 ET | 1464 | 20.38 |
10:28 ET | 2820 | 20.37 |
10:30 ET | 700 | 20.37 |
10:32 ET | 14459 | 20.29 |
10:33 ET | 2314 | 20.335 |
10:35 ET | 1884 | 20.33 |
10:37 ET | 9707 | 20.27 |
10:39 ET | 4813 | 20.27 |
10:42 ET | 2300 | 20.29 |
10:44 ET | 1980 | 20.27 |
10:46 ET | 300 | 20.28 |
10:48 ET | 501 | 20.27 |
10:50 ET | 1052 | 20.27 |
10:51 ET | 7855 | 20.15 |
10:53 ET | 1778 | 20.16 |
10:55 ET | 400 | 20.16 |
10:57 ET | 200 | 20.16 |
11:00 ET | 1165 | 20.17 |
11:02 ET | 7303 | 20.13 |
11:04 ET | 716 | 20.135 |
11:08 ET | 676 | 20.02 |
11:09 ET | 1421 | 20.04 |
11:11 ET | 100 | 20.035 |
11:13 ET | 775 | 20.03 |
11:15 ET | 2641 | 19.985 |
11:18 ET | 2943 | 20.05 |
11:20 ET | 764 | 20 |
11:22 ET | 200 | 19.97 |
11:24 ET | 2754 | 19.98 |
11:26 ET | 3505 | 19.96 |
11:27 ET | 300 | 19.94 |
11:29 ET | 2566 | 19.97 |
11:33 ET | 1131 | 19.955 |
11:36 ET | 1907 | 19.89 |
11:38 ET | 3281 | 19.915 |
11:42 ET | 804 | 19.93 |
11:44 ET | 10440 | 19.9 |
11:45 ET | 3360 | 19.8631 |
11:47 ET | 9583 | 19.87 |
11:49 ET | 1110 | 19.885 |
11:51 ET | 602 | 19.85 |
11:54 ET | 201 | 19.84 |
11:56 ET | 2080 | 19.808 |
11:58 ET | 701 | 19.8 |
12:00 ET | 100 | 19.8 |
12:02 ET | 6112 | 19.838 |
12:03 ET | 1256 | 19.84 |
12:05 ET | 1303 | 19.805 |
12:07 ET | 300 | 19.805 |
12:09 ET | 400 | 19.81 |
12:12 ET | 501 | 19.8 |
12:14 ET | 2135 | 19.805 |
12:16 ET | 968 | 19.78 |
12:18 ET | 1693 | 19.762 |
12:20 ET | 441 | 19.76 |
12:21 ET | 100 | 19.76 |
12:23 ET | 4727 | 19.7675 |
12:25 ET | 11327 | 19.865 |
12:27 ET | 738 | 19.865 |
12:30 ET | 2184 | 19.88 |
12:34 ET | 1878 | 19.84 |
12:36 ET | 3910 | 19.81 |
12:38 ET | 1988 | 19.785 |
12:39 ET | 200 | 19.79 |
12:41 ET | 2170 | 19.8 |
12:43 ET | 948 | 19.78 |
12:45 ET | 870 | 19.76 |
12:48 ET | 300 | 19.76 |
12:50 ET | 3784 | 19.77 |
12:52 ET | 2683 | 19.775 |
12:54 ET | 2103 | 19.82 |
12:56 ET | 522 | 19.79 |
12:57 ET | 100 | 19.795 |
12:59 ET | 490 | 19.81 |
01:01 ET | 1000 | 19.835 |
01:06 ET | 700 | 19.835 |
01:08 ET | 300 | 19.85 |
01:10 ET | 100 | 19.86 |
01:12 ET | 600 | 19.84 |
01:14 ET | 507 | 19.8325 |
01:15 ET | 600 | 19.82 |
01:17 ET | 1571 | 19.85 |
01:19 ET | 600 | 19.855 |
01:21 ET | 1981 | 19.85 |
01:24 ET | 927 | 19.8 |
01:26 ET | 700 | 19.815 |
01:28 ET | 1222 | 19.8 |
01:30 ET | 1728 | 19.775 |
01:32 ET | 100 | 19.78 |
01:33 ET | 800 | 19.83 |
01:35 ET | 200 | 19.86 |
01:37 ET | 2300 | 19.83 |
01:39 ET | 100 | 19.84 |
01:42 ET | 1098 | 19.87 |
01:46 ET | 400 | 19.88 |
01:48 ET | 253 | 19.8649 |
01:50 ET | 200 | 19.86 |
01:51 ET | 1619 | 19.88 |
01:53 ET | 1700 | 19.93 |
01:55 ET | 703 | 19.94 |
01:57 ET | 300 | 19.92 |
02:00 ET | 200 | 19.92 |
02:02 ET | 300 | 19.925 |
02:04 ET | 2542 | 20 |
02:06 ET | 400 | 20 |
02:08 ET | 2926 | 20.025 |
02:09 ET | 2442 | 20.05 |
02:11 ET | 605 | 20.03 |
02:13 ET | 1292 | 20.105 |
02:15 ET | 975 | 20.08 |
02:18 ET | 100 | 20.09 |
02:20 ET | 1376 | 20.02 |
02:22 ET | 200 | 20.01 |
02:24 ET | 840 | 19.99 |
02:26 ET | 2100 | 20 |
02:27 ET | 509 | 20.01 |
02:29 ET | 200 | 20.009 |
02:31 ET | 1200 | 19.99 |
02:33 ET | 699 | 19.96 |
02:36 ET | 300 | 19.94 |
02:38 ET | 900 | 19.91 |
02:40 ET | 2596 | 19.94 |
02:44 ET | 354 | 19.948 |
02:45 ET | 600 | 19.92 |
02:47 ET | 1040 | 19.88 |
02:49 ET | 300 | 19.88 |
02:51 ET | 223 | 19.87 |
02:54 ET | 1800 | 19.93 |
02:56 ET | 600 | 19.91 |
02:58 ET | 100 | 19.919 |
03:00 ET | 1000 | 19.92 |
03:02 ET | 534 | 19.91 |
03:03 ET | 200 | 19.94 |
03:05 ET | 100 | 19.95 |
03:07 ET | 5460 | 20.03 |
03:09 ET | 3095 | 20.04 |
03:12 ET | 800 | 20.07 |
03:14 ET | 2674 | 20.09 |
03:16 ET | 1907 | 20.09 |
03:18 ET | 200 | 20.09 |
03:20 ET | 1504 | 20.07 |
03:21 ET | 2362 | 20.045 |
03:23 ET | 1500 | 20.075 |
03:25 ET | 4941 | 20.03 |
03:27 ET | 9104 | 19.98 |
03:30 ET | 3588 | 20.02 |
03:32 ET | 900 | 20.04 |
03:34 ET | 2040 | 20.03 |
03:36 ET | 1514 | 20.03 |
03:38 ET | 8552 | 20.08 |
03:39 ET | 3100 | 20.119 |
03:41 ET | 4451 | 20.17 |
03:43 ET | 6452 | 20.155 |
03:45 ET | 3791 | 20.15 |
03:48 ET | 7367 | 20.18 |
03:50 ET | 1500 | 20.2 |
03:52 ET | 9087 | 20.25 |
03:54 ET | 8110 | 20.31 |
03:56 ET | 11799 | 20.24 |
03:57 ET | 35378 | 20.375 |
03:59 ET | 156797 | 20.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Denali Therapeutics Inc | 3.0B | -21.2x | --- |
MorphoSys AG | 2.7B | -5.5x | --- |
Amicus Therapeutics Inc | 3.0B | -20.4x | --- |
Genmab A/S | 17.4B | 21.7x | +22.71% |
Twist Bioscience Corp | 2.9B | -14.6x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -5.9x | --- |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -21.2x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.